STIOLTO RESPIMAT
LAMALABA SMI
Tiotropium bromide / Olodaterol · Boehringer Ingelheim
Active Medication & Mechanism
- Tiotropium bromide monohydrate LAMA2.5 mcg per actuation
Long-acting muscarinic antagonist. Blocks M3 receptors on airway smooth muscle with slow dissociation, providing 24-hour bronchodilation.
- Olodaterol hydrochloride LABA2.5 mcg per actuation
Long-acting beta2-adrenergic agonist. Provides sustained bronchodilation (24 hours) through selective beta2-receptor stimulation on airway smooth muscle.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
2.5/2.5 mcg
2 puffs (5/5 mcg total) once daily at the same time each day → 5/5 mcg
FDA Approved
Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Not Approved
Stiolto Respimat is NOT indicated for asthma. LABA without ICS increases risk of serious asthma events.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
2.5/2.5 mcg 2 puffs (5/5 mcg total) once daily at the same time each day → 5/5 mcg
COPD FDA Approved
Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Asthma Not Approved
Stiolto Respimat is NOT indicated for asthma. LABA without ICS increases risk of serious asthma events.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute bronchospasm. Use a SABA.